Summary:
- This article discusses concerns about the safety of selective serotonin reuptake inhibitors (SSRIs), a class of antidepressant medications, and the role of the U.S. Food and Drug Administration (FDA) in regulating these drugs.
- It highlights the findings of a report by the consumer advocacy group Public Citizen, which alleges that the FDA has failed to adequately address the risks associated with SSRIs, including increased suicidal behavior in young people and other adverse effects.
- The article suggests that the FDA has prioritized the interests of pharmaceutical companies over public health, and calls for greater transparency and accountability in the drug approval and safety monitoring processes.